Associated Papers
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.
Wang Z et al.
Molecular Biomedicine, 2022
Durable response to crizotinib in an advanced lung adenocarcinoma patient harboring rare CD47-MET fusion: a case report.
Liu J et al.
Translational Cancer Research, 2022
MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.
Lee M et al.
Expert Opinion on Therapeutic Targets, 2021
MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Guo R et al.
Nature Reviews. Clinical Oncology, 2020
A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.
Tiedt R et al.
Cancer Research, 2011
21697284 (PubMed )
Supplement: 00085472can104433-sup-f2_t4_meth.pdf
Select a paper to view details